Molecular Imaging, Inc., an Ann Arbor, MI-based specialty contract research organization (CRO), has raised $9.9m in Series A financing round.
Founded in 2003 and led by by president and CEO Tom Ludlam, Molecular Imaging provides in vivo preclinical imaging services to the pharmaceutical and biotechnology industries to enhance early-stage R&D decision-making. The company has a proven track record of imaging and discovery expertise in oncology and inflammation and is extending its imaging efforts into other therapeutic areas.
Its imaging modalities include MRI, micro-PET, bioluminescence, fluorescence (two- and three-dimensional with fluorescence molecular tomography) and micro-CT
Michael Gross, managing director for Beringea, is now a director of Molecular Imaging.